The eFlow® was developed in partnership with PARI GmbH, applying TTP’s proprietary electronic atomiser technology, TouchSpray™, to create an innovative inhalation system for the treatment of respiratory diseases.
You breathe in. You breathe out. This happens about 20,000 times a day, without a second thought. But if you have cystic fibrosis, chronic asthma, or another respiratory disease, it’s a different story. You may need a regular dose of drugs delivered straight into your lungs, just to keep you alive.
Deep lung penetration requires a highly controlled droplet size — too small and the droplets are exhaled, too large and they’ll land in the back of the throat.
TTP’s challenge was to find a better way to deliver liquid-phase drugs directly into the lungs, one that would increase drug efficacy and eliminate propellant gases.
The solution was TouchSpray™, a chamberless, planar nozzle plate driven by a piezoelectric actuator. The inertial transfer mechanism generates a highly defined aerosol of liquid droplets at the touch of a button.
The invention of this breakthrough technology ultimately led to the global launch of the PARI eFlow® electronic nebuliser — a new inhaler that cuts patient treatment time by an amazing 50%. The drug delivery technology used in the PARI eFlow® electronic nebuliser enables liquid medication to be absorbed through the lungs with as much as 90% efficacy.
What makes the Pari eFlow® different?
- Reduces treatment time by more than 50%
- Silent, discreet operation
- Battery-powered and easily portable
- Interchangeable spray heads allow easy cleaning
- More reliable and serviceable than traditional compressor-based systems
- Designed for use with all inhalation medications approved in Europe.
